ADARx Pharmaceuticals (ADRX) vs UroGen Pharma (URGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
ADARx Pharmaceuticals is the larger company by market cap ($1.88 billion vs $1.81 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADRX | URGN |
|---|---|---|
| Share price | $17.58 | $37.06 |
| Market cap | $1.88B | $1.81B |
| 1-day change | -0.54% | +0.22% |
| YTD return | — | +57.90% |
| 1-year return | — | +113.39% |
| 5-year return | — | +117.27% |
| Forward P/E | — | 13.26 |
| EPS (TTM) | $-1.16 | $-1.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $109.79M |
| Revenue growth (YoY) | — | +21.45% |
| Net income (latest FY) | — | $-153.49M |
| Gross margin | — | 88.66% |
| Operating margin | — | -113.73% |
| Net margin | — | -139.81% |
| 52-week high | $23.21 | $50.81 |
| 52-week low | $16.64 | $15.86 |
| Distance from 52-week high | -24.26% | -27.06% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +61.90% |
| Average volume | 1.25M | 849.01K |
| Shares outstanding | 106.80M | 48.88M |
| Employees | 100 | 300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ADARx Pharmaceuticals
ADRX stock →ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
ADRX vs URGN FAQ
Which is bigger, ADARx Pharmaceuticals or UroGen Pharma?
ADARx Pharmaceuticals (ADRX) is larger, with a market capitalization of $1.88B compared with $1.81B for UroGen Pharma (URGN).
Are ADARx Pharmaceuticals and UroGen Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.